Characterization of Amphetamine, Methylphenidate, Nicotine, and Atomoxetine on Measures of Attention, Impulsive Action, and Motivation in the Rat: Implications for Translational Research
Authors:
Open Access
- 24 April 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 427
Abstract
Amphetamine (AMP), methylphenidate (MPH), and atomoxetine (ATX) are approved treatments for ADHD, and together with nicotine (NIC), represent pharmacological agents widely studied on cognitive domains including attention and impulsive action in humans. These agents thus represent opportunities for clinical observation to be reinvestigated in the preclinical setting, i.e., reverse translation. The present study investigated each drug in male, Long Evans rats trained to perform either (1) the five-choice serial reaction time task (5-CSRTT), (2) Go/NoGo task, or (3) a progressive ratio (PR) task, for the purpose of studying each drug on attention, impulsive action and motivation. Specific challenges were adopted in the 5-CSRTT designed to tax attention and impulsivity, i.e., high frequency of stimulus presentation (sITI), variable reduction in stimulus duration (sSD), and extended delay to stimulus presentation (10-s ITI). Initially, performance of a large (> 80) cohort of rats in each task variant was conducted to examine performance stability over repeated challenge sessions, and to identify subgroups of “high” and “low” attentive rats (sITI and sSD schedules), and “high” and “low” impulsives (10-s ITI). Using an adaptive sequential study design, the effects of AMP, MPH, ATX, and NIC were examined and contrasting profiles noted across the tests. Both AMP (0.03–0.3 mg/kg) and MPH (1–6 mg/kg) improved attentional performance in the sITI but not sSD or 10-s ITI condition, NIC (0.05–0.2 mg/kg) improved accuracy across all conditions. ATX (0.1–1 mg/kg) detrimentally affected performance in the sITI and sSD condition, notably in “high” performers. In tests of impulsive action, ATX reduced premature responses notably in the 10-s ITI condition, and also reduced false alarms in Go/NoGo. Both AMP and NIC increased premature responses in all task variants, although AMP reduced false alarms highlighting differences between these two measures of impulsive action. The effect of MPH was mixed and appeared baseline dependent. ATX reduced break point for food reinforcement suggesting a detrimental effect on motivation for primary reward. Taken together these studies highlight differences between AMP, MPH, and ATX which may translate to their clinical profiles. NIC had the most reliable effect on attentional accuracy, whereas ATX was reliably effective against all tests of impulsive action.Keywords
This publication has 132 references indexed in Scilit:
- Differential Sensitivity to Psychostimulants Across Prefrontal Cognitive Tasks: Differential Involvement of Noradrenergic α1- and α2-ReceptorsBiological Psychiatry, 2012
- Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in ratsPsychopharmacology, 2011
- On the improvement of inhibitory response control and visuospatial attention by indirect and direct adrenoceptor agonistsPsychopharmacology, 2011
- Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonistsPsychopharmacology, 2011
- Comparative effects of different test day challenges on performance in the 5-choice serial reaction time task.Behavioral Neuroscience, 2011
- Meta-analysis of the acute effects of nicotine and smoking on human performancePsychopharmacology, 2010
- Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorderADHD Attention Deficit and Hyperactivity Disorders, 2009
- Defining the Role of Pharmacology in the Emerging World of Translational Research2009
- Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal ModelsNeuropsychopharmacology, 2008
- The ultimate model organism: progress in experimental medicineNature Reviews Drug Discovery, 2005